Ken Mestemacher's questions to InMed Pharmaceuticals (INM) leadership • Q2 2022
Question
Ken Mestemacher of Edison Group questioned the rationale for selecting CBDV and THCV as the next product launches and their pricing dynamics. He also asked about the ideal timing for partnering the INM-088 glaucoma program and sought details on the role of the newly hired VP of Sales and Marketing.
Answer
CEO Eric Adams and Shane Johnson, SVP and GM of BayMedica, explained that CBDV and THCV were chosen due to strong customer demand and existing scientific data supporting their use cases, with current market prices around $25,000 per kilogram. Regarding the glaucoma program, Eric Adams and Eric Hsu, SVP of Preclinical R&D, noted that partnerships in the ocular space can occur early, even preclinically. Shane Johnson detailed that the new VP of Sales, Jerry Griffin, will spearhead all sales and marketing efforts, focusing on expanding within the wellness channel and opening new markets like personal care and food & beverage.